BRAF and cholangiocarcinoma: Additionally, the treatment with the oral BRAF inhibitor vemurafenib led to a partial response in one patient among eight patients with BRAF V600-mutated CCA, even though BRAF mutations predominantly occur in iCCA at low frequency (3–5%) [106,107,108].